
Inflammatory bowel disease: Good compliance with vedolizumab therapy
Vedolizumab, a monoclonal antibody has a higher 1- and 2-year persistence compared to two tumor necrosis factor inhibitors (anti-TNF, TNFi) in both Crohn’s disease and ulcerative colitis, according to the results of a meta-analysis. The result mainly affects bionaive patients; the advantage of vedolizumab over the two TNFis—infliximab and adalimumab—was more pronounced in ulcerative colitis […]